GlassScriptPhysician profile
Farhad Sanati
NPI 1770004558
$1,878.19
in general payments reported to CMS, 2019-2025
27 companies · $414 in 2025
The $414 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $20.82 · 2022: $177 · 2023: $712 · 2024: $554 · 2025: $414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,482 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,481.57 |
| Education | $198.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $308.55 | 2022-2025 | |
| Lilly USA, LLC | $226.93 | 2022-2024 | Retevmo, Jaypirca, Verzenio |
| Incyte Corporation | $201.98 | 2023 | Jakafi |
| Novartis Pharmaceuticals Corporation | $167.49 | 2023-2025 | |
| Eisai INC. | $124.94 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $102.56 | 2022-2025 | Keytruda, Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $98.31 | 2023-2025 | Fruzaqla, Ninlaro, Alunbrig |
| Astrazeneca Pharmaceuticals LP | $88.18 | 2022-2025 | Imfinzi, Wainua |
| Seagen INC. | $64.95 | 2023 | Padcev, Adcetris, Tukysa |
| Genentech USA, INC. | $57.59 | 2024 | Tecentriq, Alecensa, Polivy |
| Daiichi Sankyo INC. | $49.80 | 2022-2024 | Enhertu |
| Janssen Biotech, INC. | $44.21 | 2022-2025 | Rybrevant |
| Emd Serono, INC. | $40.09 | 2023-2025 | Tepmetko |
| Astellas Pharma US INC | $27.69 | 2025 | Xtandi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.75 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $25.83 | 2023 | Neulasta, Avastin, Neupogen |
| Servier Pharmaceuticals LLC | $24.70 | 2024 | |
| Pharmaand Gmbh | $21.42 | 2025 | Rubraca |
| Genzyme Corporation | $20.92 | 2023 | |
| Amgen INC. | $20.82 | 2020 | |
| Sobi, INC | $20.76 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.65 | 2022 | |
| Jazz Pharmaceuticals INC. | $20.05 | 2024 | |
| Tolmar, INC. | $20.04 | 2025 | Rubraca, Eligard |
| Puma Biotechnology, INC. | $20.00 | 2024 | |
| Taiho Oncology, INC. | $17.18 | 2025 | |
| Recordati_rare_diseases_inc. | $15.80 | 2025 | Enjaymo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farhad Sanati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.